This clinical trial focuses on patients with newly diagnosed advanced ovarian cancer, peritoneal cancer, or fallopian tube cancer. The study compares two treatment approaches using several medications. All patients will initially receive chemotherapy with carboplatin and paclitaxel, which are standard cancer drugs given through an intravenous infusion.
After the initial chemotherapy, patients will be divided into two groups. One group will receive a medication called niraparib alone, while the other group will receive niraparib combined with bevacizumab. Niraparib is taken as a capsule by mouth, while bevacizumab is given through an intravenous infusion. The purpose of this study is to determine if adding bevacizumab to niraparib treatment leads to better results than using niraparib alone.
The study will monitor how long patients remain without their cancer getting worse. Patients will receive regular medical examinations and tests throughout the study period. The treatment may continue for up to 36 months, depending on how well patients respond to the therapy and whether they experience any side effects.



Belgium
Czechia
Germany
Italy